22 September 2016Americas

Allergan to acquire Tobira for $1.7bn

Allergan has entered into an agreement to acquire Tobira Therapeutics for up to $1.7 billion.

The acquisition, which is Allergan’s third this month, will allow it to develop therapies for treating nonalcoholic steatohepatitis (NASH), a fatty liver disease closely linked to obesity.

Allergan has also announced that it will pay up to $50 million for Akarna Therapeutics, another company that is working on a treatment for NASH.

The buyout adds Cenicriviroc and Evogliptin, two complementary development programmes for treating NASH, to Allergan’s global gastroenterology research and development (R&D) pipeline.

President of Allergan, Brent Saunders, said in a statement: “The acquisition of Tobira is a strategic R&D investment within a white space area of our global gastroenterology franchise and an opportunity to advance the development of novel treatments for NASH.”

He added: “With the increasing rates of diabetes, obesity and other metabolic conditions in the US and in developed nations globally, NASH is set to become one of the next epidemic-level chronic diseases we face as a society.

“It is important that we invest in new treatments today so that healthcare systems, providers and patients have treatment options to face this challenge in the coming years.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk